Depressed in-patients respond differently
to imipramine and mirtazapine
by
Bruijn JA, Moleman P, Mulder PG, van den Broek WW
Department of Psychiatry,
"Dijkzigt" University Hospital,
Rotterdam, The Netherlands.
Pharmacopsychiatry 1999 May; 32(3):87-92

ABSTRACT

Tricyclic antidepressants and more recent antidepressants are generally considered to have equivalent efficacy in the treatment of depression. After a previous report of a marked difference in the response to mirtazapine compared to imipramine, we report here an analysis of different symptom clusters. One hundred seven consecutive in-patients with major depression (Diagnostic and Statistical Manual III-R, DSM-III-R) and a Hamilton Rating Scale for Depression (HRS-D) score of 18 points or more were randomly assigned to double-blind treatment. Two and four weeks after predefined blood levels had been obtained, the severity of depression was assessed using the HRS-D. The mean dosages used were 235 mg/day of imipramine and 77 mg/day of mirtazapine, the latter being in excess of the 15-45 mg/day range currently advised. Total HRS-D scores and seven symptom clusters were analyzed in the 85 patients (79%) who were not receiving any co-medication. Imipramine was more effective against the clusters related to core symptoms of depression: "depression and guilt", "retardation", and "melancholia", respectively. Mirtazapine showed a biphasic response with regard to the clusters "sleep" and "anxiety/agitation", respectively, which consisted of a marked response after two weeks of predefined blood level, but with a waning of this effect at four weeks. Imipramine produced a more gradual response on these clusters, which was more pronounced at four weeks than with mirtazapine. Two aspects of the present study could be related to this finding: blood level control resulted in optimal treatment with imipramine but not mirtazapine, and - most importantly - the patients were not receiving any anxiolytic or hypnotic co-medication. These findings suggest that mirtazapine may have anxiolytic and sedative properties and fewer antidepressant properties than imipramine in severely depressed in-patients.

TCAs
SSRIs
Options
Anhedonia
Imipramine
Melancholy
Mirtazapine
Mirtazapine v SSRIs
Mirtazapine: overview
Mirtazapine: structure
Mirtazapine v venlafaxine
Imipramine and depression
Mirtazapine and depression
Antidepressant mechanisms
Mirtazapine and the receptors
Mirtazapine: pharmacokinetics
Mirtazapine and sexual behaviour
Amitriptyline (Elavil) plus mirtazapine (Remeron)
Mirtazapine as an antidepressant: safety and efficacy
How effective are commonly prescribed antidepressants?